Tivozanib, a cancer drug developed by AVEO Pharmaceuticals (NASDAQ:AVEO) and Astellas Pharma, is currently under FDA review. Shares of AVEO fell by 5% today after reporting its Q4 results and offering additional details from tivozanib's phase 3 clinical trial. This news has largely been expected by investors since last summer, and health care analyst Max Macaluso breaks down what happened today in this video.
- Feb 13, 2013 at 6:00PM
- Health Care